Wrong cost-effectiveness analysis
Issue #286
new
In this network, we assume that we know, before applying the therapy, whether the disease is present or not. Therefore, it is not worth doing the test. However, OM recommends doing the test when the willingness to pay is above 8.44e16. It seems to be due to the loss of precision when doing calculations with very large numbers.
Comments (2)
-
reporter -
reporter -
assigned issue to
-
assigned issue to
- Log in to comment